|
KR102656470B1
(ko)
|
2014-12-10 |
2024-04-09 |
리전츠 오브 더 유니버스티 오브 미네소타 |
질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기
|
|
AU2016261600B2
(en)
|
2015-05-08 |
2021-09-23 |
President And Fellows Of Harvard College |
Universal donor stem cells and related methods
|
|
HK1257295A1
(zh)
|
2015-12-04 |
2019-10-18 |
Novartis Ag |
用於免疫肿瘤学的组合物和方法
|
|
EP3568464A1
(en)
*
|
2017-01-13 |
2019-11-20 |
The Regents of The University of California |
Immunoengineered pluripotent cells
|
|
AU2018239320B2
(en)
*
|
2017-03-20 |
2024-10-31 |
Washington University |
Cells and methods of uses and making the same
|
|
EP3601561A2
(en)
|
2017-03-22 |
2020-02-05 |
Novartis AG |
Compositions and methods for immunooncology
|
|
WO2018227286A1
(en)
|
2017-06-12 |
2018-12-20 |
Sinai Health System |
Allograft tolerance without the need for systemic immune suppression
|
|
WO2019014564A1
(en)
|
2017-07-14 |
2019-01-17 |
Editas Medicine, Inc. |
SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
|
|
EP3824074A4
(en)
*
|
2018-07-17 |
2022-04-20 |
The Regents of The University of California |
Cells differentiated from immunoengineered pluripotent cells
|
|
EA202190295A1
(ru)
*
|
2018-07-17 |
2021-06-11 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Т-клетки с химерным антигенным рецептором, происходящие от плюрипотентных стволовых клеток, полученных посредством иммуноинженерии
|
|
US12378572B2
(en)
|
2018-09-07 |
2025-08-05 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
WO2020067993A1
(en)
*
|
2018-09-26 |
2020-04-02 |
National University Of Singapore |
Engineered human mesenchymal stromal cells with low immunogenicity, methods and kits of generating the same
|
|
UY38427A
(es)
*
|
2018-10-26 |
2020-05-29 |
Novartis Ag |
Métodos y composiciones para terapia con células oculares
|
|
CN111424016A
(zh)
*
|
2019-01-09 |
2020-07-17 |
复旦大学 |
降低细胞免疫原性的诱导型多能干细胞系及建立方法
|
|
CA3130398A1
(en)
*
|
2019-02-15 |
2020-08-20 |
President And Fellows Of Harvard College |
Universal donor stem cells and related methods
|
|
EP3966316A4
(en)
|
2019-05-10 |
2023-01-25 |
The Regents of The University of California |
MODIFIED PLURIPOTENT CELLS
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
AU2020307550A1
(en)
|
2019-06-26 |
2022-02-03 |
The Regents Of The University Of California |
SIRPalpha-silenced natural killer (NK) cells
|
|
TW202115245A
(zh)
*
|
2019-06-27 |
2021-04-16 |
丹麥商諾佛 儂迪克股份有限公司 |
安全免疫隱形細胞
|
|
EP4022037A1
(en)
|
2019-07-10 |
2022-07-06 |
Helmuth Heinrich Kunz |
Methods for deriving autologous and hypoimmunogenic hair follicle containing sheets in vitro
|
|
US20220267732A1
(en)
|
2019-08-01 |
2022-08-25 |
Sana Biotechnology, Inc. |
Dux4 expressing cells and uses thereof
|
|
JP7728747B2
(ja)
|
2019-08-23 |
2025-08-25 |
サナ バイオテクノロジー，インコーポレイテッド |
Ｃｄ２４発現細胞およびそれらの用途
|
|
EP4025224A1
(en)
|
2019-09-05 |
2022-07-13 |
CRISPR Therapeutics AG |
Universal donor cells
|
|
JP7753197B2
(ja)
*
|
2019-09-05 |
2025-10-14 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
ユニバーサルドナー細胞
|
|
EP4028523A1
(en)
*
|
2019-09-09 |
2022-07-20 |
Scribe Therapeutics Inc. |
Compositions and methods for use in immunotherapy
|
|
WO2021055985A1
(en)
*
|
2019-09-22 |
2021-03-25 |
Cellerant Therapeutics, Inc. |
Ipsc-derived, hypoimmunogenic, myeloid progenitor cells
|
|
AU2020365937A1
(en)
*
|
2019-10-15 |
2022-04-28 |
The Regents Of The University Of California |
Transplanted cell protection via Fc sequestration
|
|
WO2021146222A1
(en)
|
2020-01-13 |
2021-07-22 |
Sana Biotechnology, Inc. |
Modification of blood type antigens
|
|
WO2021146471A2
(en)
*
|
2020-01-15 |
2021-07-22 |
The Regents Of The University Of California |
Transplanted cell protection via inhibition of polymorphonuclear cells
|
|
TW202140784A
(zh)
|
2020-01-17 |
2021-11-01 |
美商薩那生物科技公司 |
用於調節基因表現的安全開關
|
|
CN115768446A
(zh)
*
|
2020-03-25 |
2023-03-07 |
萨那生物技术股份有限公司 |
用于治疗神经病症和疾患的低免疫原性神经细胞
|
|
JP2023521157A
(ja)
*
|
2020-04-06 |
2023-05-23 |
アールエックスセル インコーポレーテッド |
低免疫原性の細胞ならびにそれらの産生のための方法および組成物
|
|
AU2021259612A1
(en)
*
|
2020-04-21 |
2022-11-10 |
Intima Bioscience, Inc. |
Cellular vaccine platform and methods of use
|
|
WO2021231712A1
(en)
*
|
2020-05-15 |
2021-11-18 |
Rxcell Inc. |
Hypoimmunogenic cells and uses thereof in immune responses
|
|
EP4196568A1
(en)
|
2020-08-13 |
2023-06-21 |
Sana Biotechnology, Inc. |
Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
|
|
CN112342196A
(zh)
*
|
2020-08-18 |
2021-02-09 |
未来智人再生医学研究院(广州)有限公司 |
一种免疫兼容可逆的通用型多能干细胞及其应用
|
|
KR20230110258A
(ko)
*
|
2020-10-20 |
2023-07-21 |
리플레이 홀딩스, 인크. |
세포 요법을 위한 방법 및 조성물
|
|
CN114457021A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达cd47抗体的多能干细胞及其衍生物与应用
|
|
CN114525255A
(zh)
*
|
2020-10-30 |
2022-05-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-11的多能干细胞衍生物及其应用
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
TW202237827A
(zh)
|
2020-12-03 |
2022-10-01 |
美商世紀治療股份有限公司 |
經基因工程改造之細胞及其用途
|
|
CN114107211B
(zh)
*
|
2020-12-04 |
2025-09-30 |
未来智人再生医学研究院(广州)有限公司 |
一种多能干细胞及其衍生物
|
|
CN116829698A
(zh)
*
|
2020-12-07 |
2023-09-29 |
加利福尼亚大学董事会 |
通过SIRP-α衔接体的先天免疫细胞沉默
|
|
US11473060B2
(en)
|
2020-12-30 |
2022-10-18 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into NK cells
|
|
KR20230146007A
(ko)
|
2020-12-31 |
2023-10-18 |
크리스퍼 테라퓨틱스 아게 |
범용 공여자 세포
|
|
US11965022B2
(en)
|
2020-12-31 |
2024-04-23 |
Sana Biotechnology, Inc. |
Methods and compositions for modulating CAR-T activity
|
|
CA3212370A1
(en)
|
2021-03-03 |
2022-09-09 |
Sana Biotechnology, Inc. |
Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
|
|
WO2022191216A1
(ja)
*
|
2021-03-09 |
2022-09-15 |
国立研究開発法人理化学研究所 |
低免疫原性網膜色素上皮細胞の製造方法
|
|
WO2022212393A1
(en)
*
|
2021-03-30 |
2022-10-06 |
The Regents Of The University Of California |
Transplanted cell protection via modified fc receptors
|
|
US20240301375A1
(en)
*
|
2021-05-24 |
2024-09-12 |
Sangamo Therapeutics, Inc. |
Ciita targeting zinc finger nucleases
|
|
IL308097A
(en)
|
2021-05-27 |
2023-12-01 |
Sana Biotechnology Inc |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
AU2022309875A1
(en)
|
2021-07-14 |
2024-01-25 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
|
WO2023008918A1
(ko)
*
|
2021-07-28 |
2023-02-02 |
의료법인 성광의료재단 |
B2m 유전자의 발현이 저해된 유전적으로 조작된 줄기세포 및 이의 이용방법
|
|
JP2024532772A
(ja)
|
2021-08-11 |
2024-09-10 |
サナ バイオテクノロジー，インコーポレイテッド |
低免疫原性細胞における遺伝子発現を変化させるための誘導性システム
|
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
MX2024001208A
(es)
|
2021-08-11 |
2024-04-22 |
Sana Biotechnology Inc |
Celulas primarias geneticamente modificadas para terapia celular alogenica.
|
|
WO2023019225A2
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
JP2024534771A
(ja)
|
2021-08-11 |
2024-09-26 |
サナ バイオテクノロジー，インコーポレイテッド |
補体媒介性炎症反応を低減するための同種異系細胞療法のための遺伝子改変細胞
|
|
CN113801881B
(zh)
*
|
2021-08-27 |
2024-02-20 |
浙江大学 |
超级增强子基因序列在促进人b2m基因表达中的用途
|
|
WO2023069790A1
(en)
|
2021-10-22 |
2023-04-27 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
|
AU2022422147A1
(en)
|
2021-12-23 |
2024-07-04 |
Sana Biotechnology, Inc. |
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
|
|
US20250302953A1
(en)
|
2022-02-14 |
2025-10-02 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
|
AU2023220128A1
(en)
|
2022-02-17 |
2024-08-22 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
WO2023183313A1
(en)
|
2022-03-22 |
2023-09-28 |
Sana Biotechnology, Inc. |
Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
|
|
CN114958768B
(zh)
*
|
2022-06-02 |
2023-03-24 |
健颐生物科技发展(山东)有限公司 |
Fgf10旁分泌通用型人成纤维细胞制剂的制备方法
|
|
CN117343962A
(zh)
*
|
2022-06-29 |
2024-01-05 |
中国科学院上海营养与健康研究所 |
免疫兼容型人多能干细胞、其制备方法及应用
|
|
WO2024003349A1
(en)
|
2022-07-01 |
2024-01-04 |
Novo Nordisk A/S |
Enhancing neuronal differentiation of ventral midbrain neural progenitor cells
|
|
WO2024012420A1
(zh)
*
|
2022-07-11 |
2024-01-18 |
士泽生物医药（苏州）有限公司 |
一种表达faslg的通用型细胞及其制备方法
|
|
CN117431217A
(zh)
*
|
2022-07-12 |
2024-01-23 |
上海驯鹿生物技术有限公司 |
表达靶向cd5的嵌合抗原受体(car)的细胞及其应用
|
|
GB202211117D0
(en)
*
|
2022-07-29 |
2022-09-14 |
Replay Holdings Llc |
Compositions and methods for non-immunogenecity
|
|
GB202212144D0
(en)
*
|
2022-08-19 |
2022-10-05 |
Resolution Therapeutics Ltd |
Cells for therapy
|
|
WO2024097314A2
(en)
|
2022-11-02 |
2024-05-10 |
Sana Biotechnology, Inc. |
Methods and systems for determining donor cell features and formulating cell therapy products based on cell features
|
|
EP4619015A1
(en)
*
|
2022-11-15 |
2025-09-24 |
The Board of Trustees of the Leland Stanford Junior University |
Hypoallogenic-immunogenic pluripotent stem cells as anti-cancer vaccine
|
|
CN118147077B
(zh)
*
|
2022-12-07 |
2025-09-26 |
士泽生物医药（苏州）有限公司 |
一种表达gsn的通用型细胞及其制备方法
|
|
CN118207165A
(zh)
*
|
2022-12-07 |
2024-06-18 |
士泽生物医药（苏州）有限公司 |
一种表达stc1的通用型细胞及其制备方法
|
|
GB202218755D0
(en)
*
|
2022-12-13 |
2023-01-25 |
Replay Holdings Llc |
Compositions and methods for non-immunogenicity
|
|
WO2024125592A1
(zh)
*
|
2022-12-16 |
2024-06-20 |
士泽生物医药（苏州）有限公司 |
一种通用型细胞及其制备方法
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
WO2024169917A1
(zh)
*
|
2023-02-16 |
2024-08-22 |
士泽生物医药（苏州）有限公司 |
通用型细胞及其制备方法
|
|
WO2024229302A1
(en)
|
2023-05-03 |
2024-11-07 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
WO2024243236A2
(en)
|
2023-05-22 |
2024-11-28 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2025003393A1
(en)
|
2023-06-30 |
2025-01-02 |
Novo Nordisk A/S |
Enhancing neuronal differentiation of neural progenitor cells
|
|
KR102740042B1
(ko)
*
|
2023-07-12 |
2024-12-06 |
㈜바이오솔빅스 |
인간 전분화능 줄기세포로 유래된 심장 오가노이드 제조방법, 효능 및 독성 평가 기술
|
|
WO2025043172A1
(en)
|
2023-08-23 |
2025-02-27 |
Sana Biotechnology, Inc. |
Modified cd47 proteins and their uses
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
CN119351338A
(zh)
*
|
2023-09-15 |
2025-01-24 |
士泽生物医药（苏州）有限公司 |
一种表达cd300ld的低免疫原性细胞及其制备方法
|
|
WO2025096757A1
(en)
|
2023-11-01 |
2025-05-08 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cd22-targeted car t cells for the treatment of relapsed and/or refractory b cell lymphomas
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025230947A1
(en)
|
2024-04-30 |
2025-11-06 |
Satellite Biosciences, Inc. |
Engineered hepatocytes for secreting polypeptides
|
|
WO2025230941A1
(en)
|
2024-04-30 |
2025-11-06 |
Satellite Biosciences, Inc. |
Hypoimmunogenic cell mixtures and methods of use thereof
|